The inclusion of satricabtagene autoleucel (satri-cel, CT041) in the CSCO Gastric Cancer Guidelines (2026 Edition) represents a pivotal moment in the evolution of cancer treatment—not only in China, but globally.
For the first time, a CAR-T therapy targeting solid tumors has been formally acknowledged within a national clinical guideline. While listed as a guideline annotation, this inclusion reflects a critical shift: CAR-T therapy is no longer confined to experimental settings but is beginning to enter the framework of standardized clinical decision-making.
Why Guideline Inclusion Matters
Clinical guidelines such as those issued by the Chinese Society of Clinical Oncology (CSCO) play a central role in shaping treatment standards across the country. Inclusion—whether as a recommendation or annotation—requires:
- Robust clinical evidence
- Expert consensus
- Careful evaluation of safety and efficacy
The decision to include satri-cel as an annotation demonstrates both scientific rigor and clinical recognition, while maintaining appropriate caution for emerging therapies.
What the Guideline States
In the third-line treatment section for advanced gastric cancer, the guideline introduces satri-cel for patients who meet the following criteria:
- Failure of standard therapies (chemotherapy, targeted therapy, immunotherapy)
- Claudin18.2 expression (IHC 2+–3+ ≥40%)
The annotation highlights that data from the CT041-ST-01 study show:
- Significant improvement in progression-free survival (PFS)
- Overall survival (OS) benefit
- Manageable safety profile
The guideline further notes that treatment should be conducted in qualified centers capable of CAR-T cell infusion.
From “No Guidance” to Clinical Reference
Before this update, CAR-T therapy had no formal place in solid tumor treatment guidelines. Its use was limited to hematologic malignancies, where multiple CAR-T products are already recommended.
This new annotation:
- Fills a critical gap in solid tumor treatment guidance
- Provides clinicians with a reference point for patient selection
- Establishes early groundwork for future full recommendations
Clinical Evidence Supporting Inclusion
The inclusion is supported by results from the CT041-ST-01 randomized controlled trial—the first of its kind in solid tumors.
Key findings include:
- Median PFS: 9.07 vs 3.45 months
- Median OS: 14.42 vs 11.33 months
- ORR: 22% vs 4%
These outcomes demonstrate meaningful clinical benefit in a population with otherwise limited treatment options.
Implications for Clinical Practice
Although satri-cel is not yet fully approved, its presence in the guideline signals that:
- Physicians can begin considering CAR-T in treatment planning discussions
- Hospitals may prepare infrastructure for CAR-T delivery
- Patients can undergo biomarker testing (Claudin18.2) in advance
Conclusion
The inclusion of satri-cel in the CSCO Gastric Cancer Guidelines is more than symbolic—it is a foundational step toward integrating CAR-T therapy into routine oncology practice for solid tumors.
As additional data emerge and regulatory approval progresses, this annotation may evolve into a formal recommendation—further reshaping the treatment landscape for advanced gastric cancer.
